Showing 2091-2100 of 8649 results for "".
- DORC Launches EVA Aveta Trocar Cannula Systemhttps://modernod.com/news/dorc-launches-eva-aveta-trocar-cannula-system/2479129/DORC is launching the new EVA Aveta trocar cannula system, the first system to feature the patent-pending Push-Fit infusion connection, plus a laser-etched retention feature, according to a company news release. Benef
- US Patent Office Issues Notice of Allowance for Nicox’s Latanoprostene Bunod in Normal Tension Glaucomahttps://modernod.com/news/us-patent-office-issues-notice-of-allowance-for-nicoxs-latanoprostene-bunod-in-normal-tension-glaucoma/2479119/Nicoy announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the U.S. patent covering the use of latanoprostene bunod for the treatment of normal tension glaucoma. Latanoprostene bunod ophthalmic solution, 0.024%, is commercialized as Vyzulta for
- Hillrom Launches Welch Allyn PanOptic Plus Ophthalmoscopehttps://modernod.com/news/hillrom-launches-digital-physical-assessment-innovations-to-advance-connected-care/2479106/Hillrom announced technological advances to its physical assessment tools with the launch of the new Welch Allyn PanOptic Plus Ophthalmoscope and the Welch Allyn MacroView Plus Otoscope. Examining the structure of the eyes and ears is a critical part of assessing p
- Texas Eye and Cataract Clinic Now Accepting Bitcoin for LASIKhttps://modernod.com/news/texas-eye-and-cataract-clinic-now-accepting-bitcoin-for-lasik-surgery/2479096/Texas Eye and Cataract (TEC) announced that it had begun accepting payments for LASIK procedures via the cryptocurrency Bitcoin. Texas Eye and Cataract said it began accepting Bitcoin to help patients looking for innovative ways to finance their LASIK procedures. “We’ve never b
- Allergan Launches New Consumer Ad Campaign for Restasishttps://modernod.com/news/allergan-launches-new-consumer-ad-campaign-for-restasis/2479065/Allergan announced it is launching a direct-to-consumer (DTC) broadcast TV advertising campaign for Restasis (cyclosporine ophthalmic emulsion) 0.05%, launching April 2021. Restasis has been FDA approved for 17 years and is the #1 dispensed branded eye drop, prescribed
- Second Sight Medical Products Names Dean Baker and Alexandra Larson to its Board of Directorshttps://modernod.com/news/second-sight-medical-products-names-dean-baker-and-alexandra-larson-to-its-board-of-directors/2479051/Second Sight Medical Products announced that the company’s Board of Directors has appointed two new members, Dean Baker, PhD, and Alexandra Larson. Dr. Baker has also been appointed to the Audit Committee of the Board. “We are honored and excited to add these two very talented individuals
- Neurolens Announces the Launch of the nMD2 Measurement Devicehttps://modernod.com/news/neurolens-announces-the-launch-of-the-nmd2-measurement-device/2479022/Neurolens has announced the launch of the neurolens Measurement Device, Gen 2 (nMD2), an objective and repeatable way to measure binocular vision, or more specifically, eye alignment. Employing over 10,000 data points per patient, the eye tracking system can identify eye misalignment as small as
- AdHawk Microsystems Launches AdHawk MindLink Eye Tracking Researchhttps://modernod.com/news/adhawk-microsystems-launches-adhawk-mindlink-eye-tracking-research/2479002/AdHawk Microsystems announced the launch of AdHawk MindLink wearable eye tracking system. AdHawk MindLink produces accurate eye movement data to provide deep insights into human behavior, ocular, and neurological health. Delivered in the form of lightweight and comfortable glasses, the AdHawk sys
- NovaSight Announces First Pivotal Study for Lazy-Eye Digital Treatment Against Gold Standard Patchinghttps://modernod.com/news/novasight-announces-first-pivotal-study-for-lazy-eye-digital-treatment-against-gold-standard-patching/2478980/Israeli startup NovaSight has announced that it is running a large, pivotal multicenter randomized controlled trial to assess the safety and effectiveness of an eye-tracking-based treatment for amblyopia (lazy eye). This is the first pivotal study of its kind in children against the gold standard
- Allergan Launches Glaucoma in Perspective Apphttps://modernod.com/news/allergan-launches-glaucoma-in-perspective-app/2478950/Allergan has announced the launch of Glaucoma in Perspective (GiP), an app designed to help patients understand the impact of glaucoma, improve quality of life, and reduce disease progression by promoting treatment adherence. The GiP app has been produced and funded by Allergan, with consu